Parkinson's: Antibody may delay symptoms, study says
The conclusion is from a clinical trial conducted at the Roche Innovation Centre in Switzerland. The research was published in the journal Nature Medicine.
© Shutterstock
Lifestyle Parkinson
A research carried out at the Roche Innovation Center, in Switzerland, has found a monoclonal antibody that is able to reduce the symptoms of Parkinson's in patients with a rapid progression of the disease.
According to the journal Nature Medicine, the experimental therapeutic antibody is called prasinezumab and is able to bind to the alpha-synuclein protein, a key factor in the progression of the disease.
Read Also: Experts Say We Should 'Feed' the Brain with These Spices (Portuguese version)
Its effectiveness can be seen after just one year. The phase two trial, called Pasadena, analyzed the effect of this antibody on 316 patients. The treatment reduced the symptoms of rapid progression after 52 weeks.
Despite the results, investors reveal that more research is needed to confirm these effects.
"The improvement obtained is very limited with a time of only one year. It is really difficult to predict the results of this type of treatment in the long term", revealed to the HuffPost blog aggregator José Luis Lanciego, a researcher at the University of Navarra, in Spain, who did not participate in the study.
Read Also: Parkinson's. "Exercise can improve symptoms and delay its progression" (Portuguese version)
Descarregue a nossa App gratuita.
Oitavo ano consecutivo Escolha do Consumidor para Imprensa Online e eleito o produto do ano 2024.
* Estudo da e Netsonda, nov. e dez. 2023 produtodoano- pt.com